

## Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Hydromorphone 2 mg/mL Injection (DIN 02145901) manufactured by Sandoz Canada Inc., Hydromorphone Hydrochloride 1 mg/mL Injection (DIN 02514435) manufactured by Sandoz Canada Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **December 22, 2022**.

As of **December 22, 2022**, all claims for Hydromorphone Hydrochloride 1 mg/mL Injection (DIN 02514435) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

Due to the unavailability of Dexamethasone Sodium Phosphate 10 mg/mL Injection (DIN 00874582) manufactured by Sandoz Canada Inc. and pms-Dexamethasone Sodium Phosphate 10 mg/mL Injection (DIN 00783900) manufactured by Pharmascience Inc., Dexamethasone Omega 10 mg/mL Injection (DIN 02204274) manufactured by Omega Laboratories Limited will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **December 22, 2022**.

As of **December 22, 2022**, all claims for Dexamethasone Omega 10 mg/mL Injection (DIN 02204274) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

Due to the unavailability of Jamp-Tobramycin 40mg/mL Injection (DIN 02420287) manufactured by Jamp Pharma Corporation and current temporary benefit product Tobramycin 40 mg/mL Injection (DIN 02241210) manufactured by Sandoz Canada Inc., Tobramycin 40 mg/mL Injection (DIN 02502372) manufactured by Sterimax Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **December 29, 2022**.

As of **December 29, 2022**, all claims for Tobramycin 40 mg/mL Injection (DIN 02502372) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

## Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Hydromorphone 2 mg/mL Injection (DIN 02145901) manufactured by Sandoz Canada Inc., Hydromorphone HCL 2 mg/mL Injection (DIN 02460602) manufactured by Sterimax Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

*continued next page*

continued from previous page

Sandoz Canada Inc. has advised Alberta Blue Cross® that the shortage of Hydromorphone 2 mg/mL Injection (DIN 02145901) has been resolved.

As a result, Hydromorphone HCL 2 mg/mL Injection (DIN 02460602) will no longer be considered a temporary benefit for the ADBL after **February 6, 2023**.

## Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Auro Pharma Inc., Jamp Pharma Corporation, Pharmascience Inc. and Sandoz Canada Inc. that the shortage for Auro-Losartan 100 mg Tablet (DIN 02403358), Jamp-Losartan 100 mg Tablet (DIN 02398850), pms-Losartan 100 mg Tablet (DIN 02309777) and Sandoz Losartan 100 mg Tablet (DIN 02313359), respectively, has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 23, 2023**. The following grouping was removed from the Critical Supply Product List **December 21, 2022**.

### LOSARTAN POTASSIUM

#### 100 MG TABLET

00002379058	APO-LOSARTAN	APX	\$ 0.1616
00002403323	AURO-LOSARTAN	AUR	\$ 0.1616
00002398834	JAMP-LOSARTAN	JPC	\$ 0.1616
00002388790	LOSARTAN	SIV	\$ 0.1616
00002388863	LOSARTAN	SNS	\$ 0.1616
00002405733	MINT-LOSARTAN	MPI	\$ 0.1616
00002309750	PMS-LOSARTAN	PMS	\$ 0.1616
00002313332	SANDOZ LOSARTAN	SDZ	\$ 0.1616
00002424967	SEPTA-LOSARTAN	SEP	\$ 0.1616
00002380838	TEVA-LOSARTAN	TEV	\$ 0.1616
00002182815	COZAAR	ORC	\$ 1.4504

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

